Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers

Kelly‐Anne Phillips(The University of Melbourne), John L. Hopper(Ste. Anne's Hospital), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Kate Birch(Ste. Anne's Hospital), Roger L. Milne(The University of Melbourne), Lenka Foretová(Masaryk Memorial Cancer Institute), Esther M. John, Irene L. Andrulis(University of Toronto), Anna Jakubowska(Pomeranian Medical University), Jacques Simard(Université Laval), Mary Beth Terry(Columbia University Irving Medical Center), Maartje J. Hooning(Erasmus MC Cancer Institute), Saundra S. Buys(University of Utah), Anne‐Marie Gerdes(Copenhagen University Hospital), Prue C. Weideman(Ste. Anne's Hospital), Nadine Andrieu(Inserm), Melissa C. Southey(The University of Melbourne), Debra Frost(Ste. Anne's Hospital), Caroline Seynaeve(Radboud University Nijmegen), Pascal Pujol(Inserm), Sue Anne McLachlan(The University of Melbourne), Antonis C Antoniou(University of Cambridge), Edith Olah(Ste. Anne's Hospital), Mary B. Daly(Fox Chase Cancer Center), Dominique Stoppa-Lyonnet(Ste. Anne's Hospital), David E. Goldgar(Ste. Anne's Hospital), Valérie Bonadona(Centre Léon Bérard), Douglas F. Easton(Ste. Anne's Hospital), Christian F. Singer(Ste. Anne's Hospital), Trinidad Caldés(Instituto de Investigación Sanitaria del Hospital Clínico San Carlos), Susan Peock(Cancer Research UK), Catherine Noguès(Inserm), Håkan Olsson(Nokia (Finland)), Matti A. Rookus(Ste. Anne's Hospital), Michael Friedländer(Prince of Wales Hospital)
Journal of Clinical Oncology
August 6, 2013
Cited by 171


Related Papers